BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.
INTRODUCTION: Women with HER2(+) or triple negative/basal-like (TN/BL) breast cancers succumb to their cancer rapidly due, in part to acquired Herceptin resistance and lack of TN/BL-targeted therapies. BRCA1-IRIS is a recently discovered, 1399 residue, BRCA1 locus alternative product, which while sh...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3325250?pdf=render |
id |
doaj-3225956a554e477f82956337ce290c00 |
---|---|
record_format |
Article |
spelling |
doaj-3225956a554e477f82956337ce290c002020-11-25T01:47:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3410210.1371/journal.pone.0034102BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.Yoshiko ShimizuHugh LukDavid HorioPenelope MironMichael GriswoldDirk IglehartBrenda HernandezJeffrey KilleenWael M ElShamyINTRODUCTION: Women with HER2(+) or triple negative/basal-like (TN/BL) breast cancers succumb to their cancer rapidly due, in part to acquired Herceptin resistance and lack of TN/BL-targeted therapies. BRCA1-IRIS is a recently discovered, 1399 residue, BRCA1 locus alternative product, which while sharing 1365 residues with the full-length product of this tumor suppressor gene, BRCA1/p220, it has oncoprotein-like properties. Here, we examine whether BRCA1-IRIS is a valuable treatment target for HER2(+) and/or TN/BL tumors. METHODOLOGY/PRINCIPAL FINDINGS: Immunohistochemical staining of large cohort of human breast tumor samples using new monoclonal anti-BRCA1-IRIS antibody, followed by correlation of BRCA1-IRIS expression with that of AKT1, AKT2, p-AKT, survivin and BRCA1/p220, tumor status and age at diagnosis. Generation of subcutaneous tumors in SCID mice using human mammary epithelial (HME) cells overexpressing TERT/LT/BRCA1-IRIS, followed by comparing AKT, survivin, and BRCA1/p220 expression, tumor status and aggressiveness in these tumors to that in tumors developed using TERT/LT/Ras(V12)-overexpressing HME cells. Induction of primary and invasive rat mammary tumors using the carcinogen N-methyl-N-nitrosourea (NMU), followed by analysis of rat BRCA1-IRIS and ERα mRNA levels in these tumors. High BRCA1-IRIS expression was detected in the majority of human breast tumors analyzed, which was positively correlated with that of AKT1-, AKT2-, p-AKT-, survivin, but negatively with BRCA1/p220 expression. BRCA1-IRIS-positivity induced high-grade, early onset and metastatic HER2(+) or TN/BL tumors. TERT/LT/BRCA1-IRIS overexpressing HME cells formed invasive subcutaneous tumors that express high AKT1, AKT2, p-AKT and vimentin, but no CK19, p63 or BRCA1/p220. NMU-induced primary and invasive rat breast cancers expressed high levels of rat BRCA1-IRIS mRNA but low levels of rat ERα mRNA. CONCLUSION/SIGNIFICANCE: BRCA1-IRIS overexpression triggers aggressive breast tumor formation, especially in patients with HER2(+) or TN/BL subtypes. We propose that BRCA1-IRIS inhibition may be pursued as a novel therapeutic option to treat these aggressive breast tumor subtypes.http://europepmc.org/articles/PMC3325250?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yoshiko Shimizu Hugh Luk David Horio Penelope Miron Michael Griswold Dirk Iglehart Brenda Hernandez Jeffrey Killeen Wael M ElShamy |
spellingShingle |
Yoshiko Shimizu Hugh Luk David Horio Penelope Miron Michael Griswold Dirk Iglehart Brenda Hernandez Jeffrey Killeen Wael M ElShamy BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. PLoS ONE |
author_facet |
Yoshiko Shimizu Hugh Luk David Horio Penelope Miron Michael Griswold Dirk Iglehart Brenda Hernandez Jeffrey Killeen Wael M ElShamy |
author_sort |
Yoshiko Shimizu |
title |
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. |
title_short |
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. |
title_full |
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. |
title_fullStr |
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. |
title_full_unstemmed |
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. |
title_sort |
brca1-iris overexpression promotes formation of aggressive breast cancers. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
INTRODUCTION: Women with HER2(+) or triple negative/basal-like (TN/BL) breast cancers succumb to their cancer rapidly due, in part to acquired Herceptin resistance and lack of TN/BL-targeted therapies. BRCA1-IRIS is a recently discovered, 1399 residue, BRCA1 locus alternative product, which while sharing 1365 residues with the full-length product of this tumor suppressor gene, BRCA1/p220, it has oncoprotein-like properties. Here, we examine whether BRCA1-IRIS is a valuable treatment target for HER2(+) and/or TN/BL tumors. METHODOLOGY/PRINCIPAL FINDINGS: Immunohistochemical staining of large cohort of human breast tumor samples using new monoclonal anti-BRCA1-IRIS antibody, followed by correlation of BRCA1-IRIS expression with that of AKT1, AKT2, p-AKT, survivin and BRCA1/p220, tumor status and age at diagnosis. Generation of subcutaneous tumors in SCID mice using human mammary epithelial (HME) cells overexpressing TERT/LT/BRCA1-IRIS, followed by comparing AKT, survivin, and BRCA1/p220 expression, tumor status and aggressiveness in these tumors to that in tumors developed using TERT/LT/Ras(V12)-overexpressing HME cells. Induction of primary and invasive rat mammary tumors using the carcinogen N-methyl-N-nitrosourea (NMU), followed by analysis of rat BRCA1-IRIS and ERα mRNA levels in these tumors. High BRCA1-IRIS expression was detected in the majority of human breast tumors analyzed, which was positively correlated with that of AKT1-, AKT2-, p-AKT-, survivin, but negatively with BRCA1/p220 expression. BRCA1-IRIS-positivity induced high-grade, early onset and metastatic HER2(+) or TN/BL tumors. TERT/LT/BRCA1-IRIS overexpressing HME cells formed invasive subcutaneous tumors that express high AKT1, AKT2, p-AKT and vimentin, but no CK19, p63 or BRCA1/p220. NMU-induced primary and invasive rat breast cancers expressed high levels of rat BRCA1-IRIS mRNA but low levels of rat ERα mRNA. CONCLUSION/SIGNIFICANCE: BRCA1-IRIS overexpression triggers aggressive breast tumor formation, especially in patients with HER2(+) or TN/BL subtypes. We propose that BRCA1-IRIS inhibition may be pursued as a novel therapeutic option to treat these aggressive breast tumor subtypes. |
url |
http://europepmc.org/articles/PMC3325250?pdf=render |
work_keys_str_mv |
AT yoshikoshimizu brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT hughluk brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT davidhorio brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT penelopemiron brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT michaelgriswold brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT dirkiglehart brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT brendahernandez brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT jeffreykilleen brca1irisoverexpressionpromotesformationofaggressivebreastcancers AT waelmelshamy brca1irisoverexpressionpromotesformationofaggressivebreastcancers |
_version_ |
1725015606992830464 |